Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum

Bujanda, David Aguiar; Cabrera, Daniel Pérez; Sánchez, Laura Croissier

doi:10.1097/coc.0000000000000959

Cited by 3 publications

(2 citation statements)

References 34 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Published data suggest that EGGCTs present in general an inferior prognosis than their gonadal counterparts. 8 During the last three decades, the clinical outcome of non-seminomatosus EGGCTs (NSEGGCTs) has been dramatically improved since the introduction of cisplatin-based chemotherapy. The standard chemotherapy regimen for patients with an (NSEGGCTs) consists of 3–4 cycles of bleomycin, etoposide, cisplatin (BEP).…”

Section: Discussionmentioning

confidence: 99%

Primary embryonal carcinoma of the prostate

Radovanović,

Zubelić,

Šantrić

et al. 2024

Urology Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Primary embryonal carcinoma of the prostate

Radovanović,

Zubelić,

Šantrić

et al. 2024

Urology Case Reports

View full text Add to dashboard Cite

“…11 Extragonadal germ cell tumors (GCTs) account for 5% to 8% of all GCTs, and they most frequently develop in the retroperitoneum, pineal gland, and mediastinum. [12][13][14] The risk of SPM in patients with testicular GCTs has been extensively reported. [15][16][17][18] However, there is little information on this topic in extragonadal GCTs.…”

mentioning

confidence: 99%

Second Hematologic Malignancies Associated With Primary Mediastinal Germ Cell Tumors

Aguiar-Bujanda,

Croissier-Sánchez,

Pérez-Cabrera

et al. 2023

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Background: Studies addressing second hematologic malignancies (SHMs) in patients with primary mediastinal germ cell tumors (PMGCTs) are scarce. To better describe this phenomenon, we analyzed a large case series from a population-based registry. Methods: The Surveillance, Epidemiology, and End Results database was used to report the clinical characteristics and incidence of SHMs in patients with PMGCT. Results: Among 1297 PMGCTs, 27 cases (2.08%) of SHM were found, with a median latency period of 12 months (95% CI: 5-41). All SHM occurred in males, 20 of whom (74.1%) had a previous nonseminomatous tumor. Acute myeloid leukemia was the most frequent SHM, accounting for 13 cases, 4 of which were acute megakaryoblastic leukemia that occurred within 5 months of diagnosis. The median survival after the diagnosis of SHM was 6 months (95% CI: 2-41). The risk of SHM was significantly higher than expected for the reference population, with a standardized incidence ratio of 6.21 (95% CI: 3.31-10.62) and an absolute excess risk of 19.19 per 10,000 person-years. Conclusions: Patients with PMGCT are at a higher risk of developing SHMs than the general population, particularly acute myeloid leukemia. This risk ranges from synchronous diagnosis of acute megakaryoblastic leukemia to the later onset of other hematological disorders that might be related to PMGCT therapies. Our findings may help create follow-up schedules for patients with PMGCT and raise the level of suspicion surrounding this association.

show abstract

Analysis of prognostic factors and establishment of prognostic model for primary mediastinal germ cell tumors: a case controlled study

Leng

Cui

Mai

et al. 2023

International Journal of Surgery

View full text Add to dashboard Cite

Background: The overall prognosis of primary mediastinal germ cell tumors (PMGCTs) is poor and the associated prognostic factors are not fully understood. Our goal was to investigate the prognostic factors of PMGCTs and to develop a validated prognostic prediction model. Materials and Methods: A total of 114 PMGCTs with specific pathological types were included in this study. Clinicopathological characteristics of nonseminomatous PMGCTs and mediastinal seminomas were compared using the χ 2 or Fisher’s exact test. Independent prognostic factors of nonseminomatous PMGCTs screened using the univariate and multivariate Cox regression analysis were then used to generate a nomogram. The predictive performance of the nomogram was evaluated using the concordance index, decision curve, and the area under the receiver operating characteristic curve (AUC) and validated by bootstrap resampling. The Kaplan–Meier curves of independent prognostic factors were analyzed. Results: This study included 71 cases of nonseminomatous PMGCTs and 43 cases of mediastinal seminomas. The 3-year overall survival rates for nonseminomatous PMGCTs and mediastinal seminomas patients were 54.5 and 97.4%, respectively. The overall survival prognostic nomogram for nonseminomatous PMGCTs was established by integrating independent prognostic factors, including the Moran-Suster stage, white blood cell, hemoglobin, and platelet-lymphocyte ratio. The nomogram demonstrated good performance with a concordance index of 0.760 and the 1-year and 3-year AUC values of 0.821 and 0.833, respectively. These values were better than those of the Moran-Suster stage system. The bootstrap validation had an AUC of 0.820 (0.724–0.915) and showed a well-fitting calibration curve. Besides, patients with mediastinal seminomas showed favorable clinical outcomes and all the nine patients received neoadjuvant therapy and postoperative surgery achieved pathological complete response. Conclusion: A nomogram based on staging and blood routine examination results was established to accurately and consistently predict the prognosis of patients with nonseminomatous PMGCTs.

show abstract

Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum

Cited by 3 publications

References 34 publications

Primary embryonal carcinoma of the prostate

Primary embryonal carcinoma of the prostate

Second Hematologic Malignancies Associated With Primary Mediastinal Germ Cell Tumors

Analysis of prognostic factors and establishment of prognostic model for primary mediastinal germ cell tumors: a case controlled study

Contact Info

Product

Resources

About